Severance Hospital
Seoul, 120-752, South Korea
NCT Number: NCT01414803
Although the combination of statin and fenofibrate is one of the options for patients with combined hyperlipidemia, non-lipid effects of it has not been completely understood yet. In this study we compared the effects of rosuvastatin 10 mg/fenofibrate 160 mg combination and rosuvastatin 10 mg monotherapy on muscle and liver enzyme, homocysteine levels, kidney, blood glucose control, and blood cell counts.
Looking for future studies?
Notify Me20 year–70 year
All sexes
Interventional
Phase 4
Seoul, 120-752, South Korea
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
rosuvastatin 10 mg/fenofibrate 160 mg per day
Time frame: 24 weeks after drug treatment
Yonsei University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07710898
Diabete Mellitus, Diabetes Mellitus
Lahore, Pakistan
View Trial DetailsNCT07696559
Dyslipidemias, Hyperlipidemia
Lahore, Pakistan
View Trial DetailsNCT00001154
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemia
Bethesda, Maryland, United States
View Trial DetailsNCT01212159
Dyslipidemias, Hyperlipidemia
Philadelphia, Pennsylvania, United States
View Trial Details